Biosimilar Herzuma approved in EU

14 February 2018

The European Commission (EC) has approved Herzuma (trastuzumab biosimilar) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification.

The positive decision for South Korean firm Celltrion (Kosdaq: 068270) follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on December 14, 2017. It follows the EC approval of Samsung Bioepis’ trastuzumab biosimilar, Ontruzant, in November last year.

Other biosimilars of Roche’s blockbuster breast and gastric cancer drug Herceptin include the partnership of India’s Biocon (BSE: 532523) and Netherlands-headquartered Mylan (Nasdaq: MYL), with the latter duo one of the leaders in the race for approval in the USA, where the last composition of matter patent for the original will expire in 2019.Herceptin sales in full-year 2017 grew 3% to 7.01 billion Swiss francs ($7.5 billion).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK